Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/48718
Título: Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer
Autores/as: Valerón, Pilar F. 
Chirino, Ricardo 
Fernandez, Leandro 
Torres, Santiago
Navarro Bosch, Domingo 
Aguiar Bautista, José Alberto 
Cabrera, Juan J. 
Diaz-Chico, Bonifacio N. 
DiazChico, JC 
Clasificación UNESCO: 32 Ciencias médicas
320101 Oncología
Palabras clave: Polymerase Chain-Reaction
Growth-Factor-Receptor
Neu Oncogene
Protein Overexpression
Amplification, et al.
Fecha de publicación: 1996
Publicación seriada: International Journal of Cancer 
Resumen: HER-2/neu oncogene status and total cellular p185(HER-2) content were simultaneously analyzed in 415 invasive breast-cancer specimens by differential PCR and ELISA respectively. Mathematical analysis of the data led us to establish a cut-off value of 1.7 for the ratio between the intensity of the HER-2/neu gene band and the reference gene band, to consider the HER-2/neu gene amplified, and of 260 fmol/mg protein, to consider p 185(HER-2) over-expressed. Of the 415 tumors studied, 15% showed a diverse degree of HER-2/neu gene amplification. Of these tumors, 87% showed over-expression of the p185(HER-2). Of the remaining 352 specimens that did not display HER-2/neu gene amplification, 97% showed no p185(HER-2) over-expression (P < 0.0001). In 40 selected samples with a p185(HER-2) level lower than 260 fmol/mg protein, the degree of p185(HER-2) phosphorylation was very low or undetectable. Conversely, 38 of 46 selected tumors with a p185(HER-2) level higher than 260 fmol/mg protein exhibited a considerable degree of p185(HER-2) phosphorylation (P < 0.0001). Our data suggest that: (i) differential PCR and ELISA, which are relatively simple procedures, give similar information on HER-2/neu status in breast cancer; and (ii) given the large series analyzed, the cutoff values established can be considered as safe values for determining whether, in a given tumor, the HER-2/neu oncogene is amplified or p185(HER-2) is over-expressed.
URI: http://hdl.handle.net/10553/48718
ISSN: 0020-7136
DOI: 10.1002/(SICI)1097-0215(19960117)65:2<129::AID-IJC1>3.0.CO;2-0
Fuente: International Journal Of Cancer[ISSN 0020-7136],v. 65 (2), p. 129-133 (Enero 1996)
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.